Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
Add more filters










Publication year range
2.
Br J Neurosurg ; 33(5): 536-540, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31018710

ABSTRACT

Purpose: The 2016 WHO tumour classification highlights the role of IDH1/2 gene mutation and 1p/19q co-deletion in classifying grade II/III gliomas. A recent cIMPACT-NOW update proposes the use of the term 'Not Elsewhere Classified' (NEC) for IDH-mutant, non co-deleted tumours. Here we show how the incorporation of ATRX immunohistochemistry can be used to better delineate the NEC group. Methods: Clinical data was collected for 112 patients (59% male) treated at our unit. Mutations in IDH1/2 genes were detected by pyrosequencing or immunohistochemistry, 1p/19q co-deletion was assessed with fluorescence in situ hybridisation and ATRX status was determined using immunohistochemical techniques. Tumours were grouped on the basis of molecular markers and outcomes compared. Results: The mean age of diagnosis was 42.6 years (20-73 years). There were 88 oligodendrogliomas (II = 47, III = 41), 18 diffuse astrocytomas (II = 9, III = 9) and 6 oligoastrocytomas (II = 4, III = 2). The majority of gliomas (87.5%) had mutations in IDH1/2. 1p/19q co-deletion was significantly associated with oligodendroglial morphology (p = < 0.001) and was mutually exclusive with ATRX mutation. Classification on the basis of molecular information showed a significant different in survival between the groups. Conclusions: ATRX immunohistochemisty is a useful adjunct which can be used with IDH mutation status, 1p/19q co-deletion and histological findings to further define tumour groups. More work is needed to understand the molecular profiles and prognostic implications for non co-deletion, ATRX preserved cases.


Subject(s)
Astrocytoma/genetics , Brain Neoplasms/genetics , Mutation/genetics , Oligodendroglioma/genetics , X-linked Nuclear Protein/genetics , Adult , Aged , Astrocytoma/pathology , Brain Neoplasms/pathology , Chromosome Deletion , Chromosomes, Human, Pair 1/genetics , Chromosomes, Human, Pair 19/genetics , Female , Humans , Immunohistochemistry , Isocitrate Dehydrogenase/genetics , Male , Middle Aged , Oligodendroglioma/pathology , Prognosis , Young Adult
5.
Biotech Histochem ; 88(1): 38-46, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23167625

ABSTRACT

Celecoxib is a clinically available COX-2 inhibitor that has been reported to have antineoplastic activity. It has been proposed as a preventative agent for several types of early neoplastic lesions. Earlier studies have shown that sensitivity of prostatic carcinoma (PCa) to celecoxib is associated with apoptosis; however, these studies have not demonstrated adequately whether this effect is dependent on p53 status. We studied the relation between sensitivity to celecoxib and the phenotypic p53 status of PCa cells lines, LNCaP (wild type p53), PC3 (null p53) and DU145 (mutated p53). Cellular growth was assessed at 24, 48, 72 and 96 h after celecoxib treatment at concentrations of 0, 10, 30, 50, 70 and 100 µM using an MTT assay. Cellular proliferation (Ki-67 expression) was determined by immunocytochemistry. Phenotypic expression of p53 was analyzed by western blotting. The effects of celecoxib on cellular growth and its association with p53 were assessed after down-regulation of p53 using synthetic interfering RNAs (siRNA) in LNCaP cells. Expression of p53 and COX-2 at mRNA levels was assessed by quantitative real time polymerase reaction (qRT-PCR). We found that celecoxib inhibited cellular growth and proliferation in a dose-dependent manner in all three cell lines; LNCaP cells with a native p53 were the most sensitive to celecoxib. We observed a down- regulation effect on p53 in LNCaP cells exposed to ≥ 30 µM celecoxib for 72 h, but found no significant changes in the p53 levels of DU145 cells, which have a mutated p53. Reduced COX-2 expression was found with decreased p53 in LNCaP and PC-3 cells that were exposed to ≥ 20 µM of celecoxib for 72 h, but COX-2 expression was increased in DU145 cells. All three cell lines demonstrated pan-cytotoxicity when exposed to 100 µM celecoxib. When p53 expression was inhibited using siRNA in LNCaP cells, the inhibitory effects on cellular growth usually exerted by celecoxib were not changed significantly. Celecoxib reduces the growth of prostate cancer cell lines in part by decreasing proliferation, which suggests that the inhibition of growth of LNCaP cells by celecoxib is independent of normal levels of native p53.


Subject(s)
Cell Cycle/drug effects , Cell Proliferation/drug effects , Cyclooxygenase 2 Inhibitors/pharmacology , Prostatic Neoplasms/metabolism , Pyrazoles/pharmacology , Sulfonamides/pharmacology , Apoptosis/drug effects , Celecoxib , Cell Line, Tumor , Down-Regulation/drug effects , Genes, p53 , Humans , Male , Prostatic Neoplasms/pathology
6.
Biotech Histochem ; 81(1): 51-4, 2006.
Article in English | MEDLINE | ID: mdl-16760127

ABSTRACT

It has been reported that when ovarian carcinoma cell lines are exposed to various concentrations of celecoxib, a COX-2 inhibitor, cell growth is decreased in a dose dependant manner. To examine further the effect of celecoxib, different cell densities of two carcinoma cell lines were exposed to various concentrations of celecoxib. LNCAP prostate and CAOV3 ovarian carcinoma cells were obtained from the American Type Culture Collection and maintained in Rosewell Park Memorial Institute 1640 and Dulbeceo's modified Eagle's medium, respectively. Each cell line was supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and antibiotic-antimycotic solution, and placed in a humidified atmosphere containing 5% CO2 at 37 degrees C. After each cell line reached a confluency of 70-80%, 1,000, 2,000, 3,000, 5,000, 7,000 and 10,000 cells/well were seeded in 96 well plates in 100 microl medium/per well for 24 h. Each cell line was exposed to the same concentrations of celecoxib (10-100 microM) at each cell density for 72 h. Cell growth was assessed using a tetrazolium conversion assay. A significant decrease compared to controls was observed in cell growth at each cell density of LNCAP and CAOV3 cells plated with >or=30 microM and >or=50 microM celecoxib, respectively. When the cell growth curves were compared for each cell density at the same concentration of celecoxib, a significant decrease in cell growth was observed when LNCAP cells were plated at 10,000 cells/well and exposed to 10-100 microM celecoxib. At a cell density >or= 5,000 LNCAP cells/well, the inhibitory effect of celecoxib was less. Similarly, a significant decrease in cell growth was observed in CAOV3 cells plated at 1,000 cells/well compared to other cell numbers plated at the same drug concentrations. At a cell density of > 5,000 CAOV3 cells/well, the inhibitory effect of celecoxib was significantly less compared to other cell densities at the same concentration. We observed a more sensitive decrease in cell growth in both carcinoma lines studied at a cell density of 1,000 cells/well with exposure to 10-100 microM celecoxib. Both carcinoma cell lines were less sensitive at a cell density of 5,000 cells/well. Our results suggest that the inhibitory effect of celecoxib may be affected by cell density. Therefore, careful attention must be paid to determining the appropriate cell density for cytotoxicity studies.


Subject(s)
Carcinoma/drug therapy , Carcinoma/pathology , Cell Count , Cyclooxygenase Inhibitors/pharmacology , Pyrazoles/pharmacology , Sulfonamides/pharmacology , Celecoxib , Cell Culture Techniques/methods , Cell Line, Tumor , Female , Humans
7.
Biotech Histochem ; 78(1): 17-21, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12713137

ABSTRACT

Dimethylsulfoxide (DMSO) is a well-known solvent that is commonly used in the laboratory. We selected DMSO as the vehicle for an experiment designed to determine if several nonsteroidal anti-inflammatory agents inhibit the growth of Caov-3, OVCAR-3, and SK-OV-3 ovarian carcinoma cell lines. Using the tetrazolium conversion assay, however, we observed some variability in the number of cells present in each ovarian carcinoma cell line with varying concentrations of DMSO (10(-6)-10(-2) M) compared to medium alone. Similarly, when Caov-3, OVCAR-3, and SK-OV-3 cells were treated with 10(-4) M DMSO plus medium (Dulbecco's Modified Eagle Medium with 10% fetal bovine serum) and plated on coverslips, the total number of cells present in 60 random fields increased significantly (P < 0.0001) for each ovarian carcinoma cell line treated with DMSO compared to medium alone. Ethanol did not demonstrate such prominent effects on cellular growth. Our observations are important to consider when selecting an appropriate solvent, especially for growth inhibition studies using Caov-3, OVCAR-3, and SK-OV-3 cell lines.


Subject(s)
Acetaminophen/pharmacology , Aspirin/pharmacology , Cell Culture Techniques/methods , Culture Media/pharmacology , Dimethyl Sulfoxide/pharmacology , Ethanol/pharmacology , Ovarian Neoplasms/pathology , Cell Count , Cell Division/drug effects , Cell Line, Tumor , Dose-Response Relationship, Drug , Female , Humans , Sensitivity and Specificity
8.
Gynecol Oncol ; 81(3): 373-9, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11371125

ABSTRACT

OBJECTIVE: A significant obstacle confronting the evaluation of potential chemopreventive compounds in ovarian carcinoma is the absence of an animal model of spontaneous ovarian carcinogenesis. A potential model of adenocarcinoma has been described in the laying hen (Gallus domesticus). The purpose of this study was to evaluate the immunohistochemical expression of available antibodies that have been utilized in chemoprevention studies in this potential model of epithelial carcinoma. METHODS: Two hundred 2-year-old hens were sacrificed at Auburn University in accordance with IUACUC guidelines. Of these hens, 8 animals were thought grossly to have ovarian carcinoma and ascites. The tumors from these 8 hens were fixed in neutral-buffered formalin and processed to paraffin blocks. Hematoxylin and eosin stains were used to document the histologic presence of adenocarcinoma. Immunohistochemical evaluation for expression of antigen was performed using the following antibodies: CA125, CEA, cytokeratin, EGFR, erbB-2, Ki-67, Lewis Y, p27, PCNA, Tag 72, TGF-alpha, Muc 1, and Muc 2. RESULTS: Upon microscopic examination by a pathologist eight specimens were documented as adenocarcinomas. Several antibodies to antigens that are frequently expressed in human ovarian cancer were cross-reactive in the laying hen. Of these, cytokeratin AE1/AE3, pan cytokeratin, EGFR, Lewis Y, CEA, Tag 72, and erbB-2 stained the chicken carcinomas. EGFR and p185erbB-2 stained diffusely, and cytokeratin AE1/AE3, pan cytokeratin, Lewis Y, CEA, and Tag 72 were focally positive in the tumor. The aforementioned antibodies which have been useful as surrogate endpoints in chemoprevention trials and which also stained the chicken carcinomas included PCNA, p27, and TGF-alpha Antibodies that were not cross-reactive include CA 125, Ki-67, Muc 1, and Muc 2. CONCLUSION: The data presented in this pilot study support the potential utility of an avian model of spontaneously arising adenocarcinoma in which to study chemopreventive agents. More importantly, the influence of chemoprevention protocols on the expression of relevant antigens can be determined using available antibodies that are cross-reactive in this model. Thus, changes in the phenotypic expression of surrogate endpoint biomarkers as identified by cross-reactive antibodies can aid in the development of chemoprevention trials for human ovarian cancer.


Subject(s)
Adenocarcinoma/immunology , Anticarcinogenic Agents/pharmacology , Antigens, Neoplasm/biosynthesis , Biomarkers, Tumor/biosynthesis , Disease Models, Animal , Ovarian Neoplasms/immunology , Adenocarcinoma/pathology , Adenocarcinoma/prevention & control , Animals , Antibodies, Monoclonal/immunology , Antibody Specificity , Antigens, Neoplasm/immunology , Biomarkers, Tumor/immunology , Chickens , Cross Reactions , Drug Screening Assays, Antitumor/methods , Female , Immunohistochemistry , Ovarian Neoplasms/pathology , Ovarian Neoplasms/prevention & control , Pilot Projects
9.
Oncol Rep ; 8(2): 373-9, 2001.
Article in English | MEDLINE | ID: mdl-11182059

ABSTRACT

Studies were performed to determine the effects of moderate decreases in body weight gain on mammary carcinogenesis. The levels of depressions in weight gain were those often observed in the evaluation of chemopreventive agents. In the first experiment, the effects of acute and chronic reductions of body weight gain when started after carcinogen treatment were examined in young rats (MNU at 50 days of age). Significant decreases (36%) in mammary cancers occurred in groups of rats that underwent a 12% acute reduction in body weight gain as compared with ad libitum controls. In contrast, chronic weight reductions of up to 12% had minimal effects on cancer multiplicities, while a 15% chronic reduction significantly decreased cancer numbers (26%). A second experiment evaluated the efficacy of toremifene (7.0 mg/kg diet), an estrogen/anti-estrogen, and the effect of toremifene-matched body weight gain reduction that occurred during the study. Toremifene caused a chronic reduction in body weight that resulted in a 10% decrease in final body weight at the end of the study. While toremifene-treated rats exhibited a 67% decrease in the number of mammary cancers, the rats which similarly exhibited a 10% decrease in final body weight showed only a 14% decrease in cancer number. Thus, the weight effects observed with toremifene, similar estrogens/anti-estrogens, and other classes of chemopreventive compounds (where chronic body weight reductions are 10% or less) imply that the body weight reduction has a limited effect on overall chemopreventive activity. A third study examined the effect of chronic body weight gain reduction on mammary cancers induced in older rats (MNU given at 100 days of age). This model more closely resembles the status of the breast tissue of mature women currently enrolled in clinical trials of chemopreventive agents. Under these conditions chronic reductions in body weight up to 15% had minimal effects on mammary carcinogenesis. These data further demonstrated that acute body weight reductions in young rats at the time of carcinogen treatment can be a concern in interpretation of the chemopreventive activity of an agent, but that moderate chronic depressions of body weight gain probably do not play a significant role.


Subject(s)
Adenocarcinoma/prevention & control , Anticarcinogenic Agents/pharmacology , Mammary Neoplasms, Experimental/prevention & control , Selective Estrogen Receptor Modulators/pharmacology , Toremifene/pharmacology , Weight Gain/drug effects , Adenocarcinoma/chemically induced , Adenocarcinoma/pathology , Animals , Female , Mammary Neoplasms, Experimental/chemically induced , Mammary Neoplasms, Experimental/pathology , Methylnitrosourea , Rats , Rats, Sprague-Dawley , Time Factors
10.
J Invest Dermatol ; 117(6): 1412-20, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11886502

ABSTRACT

Previous studies have shown that the protease-activated receptor 2 is involved in skin pigmentation through increased phagocytosis of melanosomes by keratinocytes. Ultraviolet irradiation is a potent stimulus for melanosome transfer. We show that protease-activated receptor 2 expression in human skin is upregulated by ultraviolet irradiation. Subjects with skin type I, II, or III were exposed to two or three minimal erythema doses of irradiation from a solar simulator. Biopsies were taken from nonexposed and irradiated skin 24 and 96 h after irradiation and protease-activated receptor 2 expression was detected using immunohistochemical staining. In nonirradiated skin, protease-activated receptor 2 expression was confined to keratinocytes in the lower one-third of the epidermis. After ultraviolet irradiation protease-activated receptor 2 expression was observed in keratinocytes in the upper two-thirds of the epidermis or the entire epidermis at both time points studied. Subjects with skin type I showed delayed upregulation of protease-activated receptor 2 expression, however, compared with subjects with skin types II and III. Irradiated cultured human keratinocytes showed upregulation in protease-activated receptor 2 expression as determined by immunofluorescence microscopy and Western blotting. Cell culture supernatants from irradiated keratinocytes also exhibited a dose-dependent increase in protease-activated receptor-2 cleavage activity. These results suggest an important role for protease-activated receptor-2 in pigmentation in vivo. Differences in protease-activated receptor 2 regulation in type I skin compared with skin types II and III suggest a potential mechanism for differences in tanning in subjects with different skin types.


Subject(s)
Melanosomes/metabolism , Receptors, Thrombin/metabolism , Skin/metabolism , Skin/radiation effects , Adult , Aged , Endopeptidases/metabolism , Female , Humans , Keratinocytes/chemistry , Keratinocytes/enzymology , Male , Middle Aged , Receptor, PAR-2 , Receptors, Thrombin/analysis , Skin/cytology , Skin Pigmentation/physiology , Skin Pigmentation/radiation effects , Ultraviolet Rays , Up-Regulation/radiation effects
11.
Anticancer Res ; 20(4): 2281-7, 2000.
Article in English | MEDLINE | ID: mdl-10953286

ABSTRACT

BACKGROUND: The effect of chemopreventive agents on cancer multiplicity is of primary interest in animal studies. The nature of data collected from chemoprevention studies may be analyzed by a longitudinal analysis of repeatedly measured cancer multiplicity data. METHODS: We determined the number of mammary cancers over the entire follow-up period for varying doses of two chemopreventive agents. Longitudinal analyses were performed to model the number of cancers over different time intervals. RESULTS: There was a significant increase in the number of cancers between six to seven weeks post-carcinogen administration in the control group. Varying patterns of cancer development were observed at different doses of chemopreventive agents including a delay in onset of tumor growth compared to the control group. CONCLUSION: Longitudinal data analysis complements traditional analyses by providing detailed information regarding the effect of chemopreventive agents on the pattern of tumor development throughout the follow-up period. Importantly, some chemopreventive agents may delay time to appearance of mammary cancers without causing a significant difference in cancer multiplicity.


Subject(s)
Anticarcinogenic Agents/pharmacology , Mammary Neoplasms, Experimental/prevention & control , Animals , Diterpenes , Female , Mammary Neoplasms, Experimental/pathology , Rats , Rats, Sprague-Dawley , Retinyl Esters , Time Factors , Triazoles/pharmacology , Vitamin A/analogs & derivatives , Vitamin A/pharmacology
12.
Carcinogenesis ; 20(1): 71-6, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9934852

ABSTRACT

These studies examined whether the small to moderate reductions in body weight gain (< or = 15%) affect mammary carcinogenesis. Beginning 1 week prior to methylnitrosourea (MNU) administration (experiment 1), rats received diets supplemented with 4-hydroxyphenylretinamide (4-HPR) (782 mg/kg of diet) and retinyl acetate (328 mg/kg of diet) or underwent food restrictions. Rats were administered an i.v. dose of MNU (50 mg/kg body wt) at 50 days of age. Although the final body weights were similarly depressed by 4-HPR (8%) and by retinyl acetate (11%) from rats fed ad libitum, the kinetics of inhibition were quite different. Whereas 4-HPR caused an acute decrease in body weight at the time it was administered, the effect of retinyl acetate was more chronic. At 110 days after the administration of MNU, the average number of mammary cancers per rat was 4.9 for rats fed ad libitum, 1.3 for rats fed 4-HPR, 3.1 when body weights were matched to 4-HPR-treated rats, 1.9 for retinyl acetate and 3.2 when body weights were matched to retinyl acetate. Experiment II was performed to determine the minimal degree of acute body weight gain reduction that would alter MNU-induced mammary carcinogenesis. Body weight gain depressions of 3, 6, 9, 12 and 15% were initiated at 43 days of age by dietary restrictions and MNU was administered at 50 days of age. At 120 days after MNU, the percentage decreases in mammary cancer multiplicity in the various groups were 14, 15, 41, 44 and 55%, respectively. These data demonstrate that moderate reductions (9-15%) in body weight gain, in particular when occurring during the initiation and early promotion stages can greatly affect cancer multiplicity.


Subject(s)
Anticarcinogenic Agents/therapeutic use , Fenretinide/therapeutic use , Food Deprivation , Mammary Neoplasms, Experimental/prevention & control , Vitamin A/analogs & derivatives , Weight Gain , Animals , Diterpenes , Energy Intake , Female , Fenretinide/administration & dosage , Mammary Neoplasms, Experimental/chemically induced , Methylnitrosourea , Rats , Rats, Sprague-Dawley , Retinyl Esters , Vitamin A/administration & dosage , Vitamin A/therapeutic use
13.
Aust N Z J Surg ; 58(9): 727-32, 1988 Sep.
Article in English | MEDLINE | ID: mdl-2854967

ABSTRACT

An early case of perianal Paget's disease is described in a 59 year old female. Literature search revealed 57 documented cases up to 1987. Diagnosis is suspected on clinical features and needs to be always confirmed by biopsy with routine stains, and, in doubtful cases, also by electron microscopy and immunohistology. The extent of the primary disease and the presence of an associated adnexal or anorectal cancer must be established. Wide surgical excision of the primary lesion, preferably with frozen section examination of the excised margins and undersurface, is the preferred treatment. Associated adnexal or anorectal cancer is treated on merit. Recurrent disease is managed by further excision, topical chemotherapy and/or laser therapy. Prognosis depends on the extent of the primary lesion, on the adequacy of the primary excision, and on the presence of an associated adnexal or anorectal cancer. In apparently cured cases, long-term surveillance is recommended.


Subject(s)
Paget Disease, Extramammary/pathology , Perineum , Skin Neoplasms/pathology , Biopsy , Female , Humans , Middle Aged , Paget Disease, Extramammary/ultrastructure , Perineum/pathology , Prognosis , Skin Neoplasms/ultrastructure
17.
Australas J Dermatol ; 15(1): 35, 1974 Apr.
Article in English | MEDLINE | ID: mdl-4370208
SELECTION OF CITATIONS
SEARCH DETAIL
...